Store	0	5	O
-	5	6	O
operated	6	14	O
calcium	15	22	B-Drug_or_compound
entry	23	28	O
promotes	29	37	O
shape	38	43	O
change	44	50	O
in	51	53	O
pulmonary	54	63	B-Cell
endothelial	64	75	I-Cell
cells	76	81	I-Cell
expressing	82	92	O
Trp1	93	97	B-Gene_or_gene_product
.	97	98	O

Activation	100	110	O
of	111	113	O
Ca2	114	117	B-Drug_or_compound
+	117	118	I-Drug_or_compound
entry	119	124	O
is	125	127	O
known	128	133	O
to	134	136	O
produce	137	144	O
endothelial	145	156	B-Cell
cell	157	161	I-Cell
shape	162	167	O
change	168	174	O
,	174	175	O
leading	176	183	O
to	184	186	O
increased	187	196	O
permeability	197	209	O
,	209	210	O
leukocyte	211	220	B-Cell
migration	221	230	O
,	230	231	O
and	232	235	O
initiation	236	246	O
of	247	249	O
angiogenesis	250	262	O
in	263	265	O
conduit	266	273	B-Cell
-	273	274	I-Cell
vessel	274	280	I-Cell
endothelial	281	292	I-Cell
cells	293	298	I-Cell
.	298	299	O

The	300	303	O
mode	304	308	O
of	309	311	O
Ca2	312	315	B-Drug_or_compound
+	315	316	I-Drug_or_compound
entry	317	322	O
regulating	323	333	O
cell	334	338	B-Cell
shape	339	344	O
is	345	347	O
unknown	348	355	O
.	355	356	O

We	357	359	O
hypothesized	360	372	O
that	373	377	O
activation	378	388	O
of	389	391	O
store	392	397	O
-	397	398	O
operated	398	406	O
Ca2	407	410	B-Drug_or_compound
+	410	411	I-Drug_or_compound
channels	412	420	O
(	421	422	O
SOCs	422	426	O
)	426	427	O
is	428	430	O
sufficient	431	441	O
to	442	444	O
promote	445	452	O
cell	453	457	B-Cell
shape	458	463	O
change	464	470	O
necessary	471	480	O
for	481	484	O
these	485	490	O
processes	491	500	O
.	500	501	O

SOC	502	505	O
activation	506	516	O
in	517	519	O
rat	520	523	B-Organism
pulmonary	524	533	B-Cell
arterial	534	542	I-Cell
endothelial	543	554	I-Cell
cells	555	560	I-Cell
increased	561	570	O
free	571	575	O
cytosolic	576	585	B-Organism_substance
Ca2	586	589	B-Drug_or_compound
+	589	590	I-Drug_or_compound
that	591	595	O
was	596	599	O
dependent	600	609	O
on	610	612	O
a	613	614	O
membrane	615	623	B-Cellular_component
current	624	631	O
having	632	638	O
a	639	640	O
net	641	644	O
inward	645	651	O
component	652	661	O
of	662	664	O
5	665	666	O
.	666	667	O
45	667	669	O
+	670	671	O
/	671	672	O
-	672	673	O
0	674	675	O
.	675	676	O
90	676	678	O
pA	679	681	O
/	681	682	O
pF	682	684	O
at	685	687	O
-	688	689	O
80	689	691	O
mV	692	694	O
.	694	695	O

Changes	696	703	O
in	704	706	O
endothelial	707	718	B-Cell
cell	719	723	I-Cell
shape	724	729	O
accompanied	730	741	O
SOC	742	745	O
activation	746	756	O
and	757	760	O
were	761	765	O
dependent	766	775	O
on	776	778	O
Ca2	779	782	B-Drug_or_compound
+	782	783	I-Drug_or_compound
entry	784	789	O
-	789	790	O
induced	790	797	O
reconfiguration	798	813	O
of	814	816	O
peripheral	817	827	B-Gene_or_gene_product
(	828	829	I-Gene_or_gene_product
cortical	829	837	I-Gene_or_gene_product
)	837	838	I-Gene_or_gene_product
filamentous	839	850	I-Gene_or_gene_product
actin	851	856	I-Gene_or_gene_product
(	857	858	O
F	858	859	B-Gene_or_gene_product
-	859	860	I-Gene_or_gene_product
actin	860	865	I-Gene_or_gene_product
)	865	866	O
.	866	867	O

Because	868	875	O
the	876	879	O
identity	880	888	O
of	889	891	O
pulmonary	892	901	O
endothelial	902	913	O
SOCs	914	918	O
is	919	921	O
unknown	922	929	O
,	929	930	O
but	931	934	O
mammalian	935	944	O
homologues	945	955	O
of	956	958	O
the	959	962	O
Drosophila	963	973	B-Organism
melanogaster	974	986	I-Organism
transient	987	996	B-Gene_or_gene_product
receptor	997	1005	I-Gene_or_gene_product
potential	1006	1015	I-Gene_or_gene_product
(	1016	1017	O
trp	1017	1020	B-Gene_or_gene_product
)	1020	1021	O
gene	1022	1026	O
have	1027	1031	O
been	1032	1036	O
proposed	1037	1045	O
to	1046	1048	O
form	1049	1053	O
Ca2	1054	1057	B-Drug_or_compound
+	1057	1058	I-Drug_or_compound
entry	1059	1064	O
channels	1065	1073	O
in	1074	1076	O
nonexcitable	1077	1089	O
cells	1090	1095	B-Cell
,	1095	1096	O
we	1097	1099	O
performed	1100	1109	O
RT	1110	1112	O
-	1112	1113	O
PCR	1113	1116	O
using	1117	1122	O
Trp	1123	1126	B-Gene_or_gene_product
oligonucleotide	1127	1142	O
primers	1143	1150	O
in	1151	1153	O
both	1154	1158	O
rat	1159	1162	B-Organism
and	1163	1166	O
human	1167	1172	B-Organism
pulmonary	1173	1182	B-Cell
arterial	1183	1191	I-Cell
endothelial	1192	1203	I-Cell
cells	1204	1209	I-Cell
.	1209	1210	O

Both	1211	1215	O
cell	1216	1220	B-Cell
types	1221	1226	O
were	1227	1231	O
found	1232	1237	O
to	1238	1240	O
express	1241	1248	O
Trp1	1249	1253	B-Gene_or_gene_product
,	1253	1254	O
but	1255	1258	O
neither	1259	1266	O
expressed	1267	1276	O
Trp3	1277	1281	B-Gene_or_gene_product
nor	1282	1285	O
Trp6	1286	1290	B-Gene_or_gene_product
.	1290	1291	O

Our	1292	1295	O
study	1296	1301	O
indicates	1302	1311	O
that	1312	1316	O
1	1317	1318	O
)	1318	1319	O
Ca2	1320	1323	B-Drug_or_compound
+	1323	1324	I-Drug_or_compound
entry	1325	1330	O
in	1331	1333	O
pulmonary	1334	1343	B-Cell
endothelial	1344	1355	I-Cell
cells	1356	1361	I-Cell
through	1362	1369	O
SOCs	1370	1374	O
produces	1375	1383	O
cell	1384	1388	B-Cell
shape	1389	1394	O
change	1395	1401	O
that	1402	1406	O
is	1407	1409	O
dependent	1410	1419	O
on	1420	1422	O
site	1423	1427	O
-	1427	1428	O
specific	1428	1436	O
rearrangement	1437	1450	O
of	1451	1453	O
the	1454	1457	O
microfilamentous	1458	1474	O
cytoskeleton	1475	1487	O
and	1488	1491	O
2	1492	1493	O
)	1493	1494	O
Trp1	1495	1499	B-Gene_or_gene_product
may	1500	1503	O
be	1504	1506	O
a	1507	1508	O
component	1509	1518	O
of	1519	1521	O
pulmonary	1522	1531	O
endothelial	1532	1543	O
SOCs	1544	1548	O
.	1548	1549	O

